Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

  • Revenue in DKK (TTM)303.14bn
  • Net income in DKK104.62bn
  • Incorporated1931
  • Employees77.41k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NOVO B:CPH since
announced
Transaction
value
Novavax Inc-Manufacturing FacilityDeal completed04 Dec 202404 Dec 2024Deal completed-43.81%200.00m
Data delayed at least 15 minutes, as of Jun 30 2025 15:59 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sanofi SA336.96bn46.39bn755.58bn84.59k16.611.4012.982.244.975.0336.1459.09------533,959.10--6.12--7.5470.9469.2313.5917.970.68826.880.220559.376.413.318.5714.0012.324.47
Pfizer Inc397.61bn50.08bn875.45bn81.00k17.551.529.302.201.381.3810.9515.890.29111.465.47771,148.103.687.454.499.4374.5769.1012.6420.370.960412.260.406664.226.849.10275.82-5.272.323.13
Gilead Sciences Inc182.92bn37.97bn876.32bn17.60k23.417.1915.754.794.734.7322.7915.390.50983.456.351,632,671.0010.585.2613.636.3878.2978.4720.7612.541.237.800.5667108.476.045.08-91.53-38.34-8.714.10
Amgen Inc217.23bn37.77bn948.57bn28.00k25.2924.0112.924.3710.9610.9663.0511.540.37431.594.581,218,786.006.518.438.5010.6664.0772.8117.3921.900.8787.060.902471.3718.577.43-39.11-12.2112.149.18
Merck & Co Inc406.90bn110.98bn1.26tn75.00k11.514.128.983.116.876.8725.1919.210.57862.315.77852,293.3015.799.5220.4612.6477.0773.4727.3017.871.1623.900.418672.966.7410.404,589.5924.64-0.58856.66
AstraZeneca plc350.03bn49.48bn1.39tn94.30k28.205.3016.903.963.633.6325.6619.300.52731.734.52425,151.407.464.3210.355.9582.3680.2214.159.390.695410.420.4348107.6818.0317.2718.1439.4313.271.20
Novo Nordisk A/S303.14bn104.62bn1.48tn77.41k18.6314.0212.474.8923.4823.4868.0331.210.76931.244.793,972,910.0026.5527.7254.1555.7484.3384.2534.5134.120.557147.340.461550.1125.0318.9420.6820.9935.5022.25
Novartis AG338.50bn81.84bn1.62tn75.88k18.836.1413.424.775.105.1021.0915.650.54752.246.47559,955.4013.249.8019.3113.0875.6673.7624.1824.420.609717.410.447866.4210.851.2439.3710.8311.064.83
Roche Holding AG481.93bn65.94bn1.70tn103.25k25.356.5516.933.5310.3210.3275.4339.940.62932.065.42585,913.709.5614.4813.9122.5173.9171.9715.1921.431.2015.670.489464.023.03-0.318-28.01-9.320.45741.51
AbbVie Inc365.18bn26.45bn2.05tn55.00k77.74226.7725.535.612.352.3532.390.8040.40253.834.701,043,036.002.955.444.067.0970.6968.897.3313.730.63597.800.9795134.963.7111.11-12.07-11.5812.037.69
Data as of Jun 30 2025. Currency figures normalised to Novo Nordisk A/S's reporting currency: Danish Krone DKK

Institutional shareholders

15.83%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Jun 2025119.13m3.51%
Norges Bank Investment Managementas of 31 Dec 202478.74m2.32%
BlackRock Fund Advisorsas of 05 Jun 202560.57m1.79%
Capital International Ltd.as of 05 Jun 202556.26m1.66%
Capital Research & Management Co. (Global Investors)as of 05 Jun 202553.66m1.58%
Capital Research & Management Co. (World Investors)as of 05 Jun 202546.39m1.37%
Geode Capital Management LLCas of 19 Jun 202536.78m1.09%
BlackRock Advisors (UK) Ltd.as of 06 Jun 202530.47m0.90%
Fundsmith LLPas of 28 Feb 202528.17m0.83%
Wellington Management Co. LLPas of 30 May 202526.26m0.78%
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.